Exemption from price control of New Bulk drugs

4608. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee in its report made recommendations for exemption of new bulk drugs developed with indigenous research and technology with indigenous research and technology from price control for a period of five years:

(b) whether it is also a fact that his Ministry has not incorporated this recommendation in the Price Control Order;

(c) whether it is a fact that similar type of provision was available under DPCO 1979;

(d) whether it is a fact that Kelkar Committee recommended decontrol of a number of drugs on the basis of this recommendation;

(e) if so, the names of those drugs the prices of which were decontrolled on this basis;

(f) whether it is also a fact that prices of a number of drugs falling under the same category remained controlled;

(g) if so, what are the names of those drugs;

(h) whether his Ministry has accepted this recommendation of Kelkar Committee; and

(i) if so what are the reasons for not incorporating it in DPCO?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes Sir.

(c) Yes, Sir.

(d) Yes, Sir.

(b) and (e) to (i) The Kelkar Committee itself excluded all such drugs while recommending drugs for price control. The Kelkar Committee recommended list of drugs for price control and the same have been included in the Second Schedule to DPCO, 1987.

Non-implementation of the directives of Courts regarding prices of finished medicines by some drug companies

4609. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1416 given in the Rajya Sabha on the 9th May, 1988 and state:

(a) whether it is a fact that M/s. Glindia, Merind, Ethnor, Hoechst and Pfizer have not implemented the prices of finished medicines fixed by Government which were upheld by the various courts;

(b) what were the prices fixed by Government for finished medicines based on Beta methasone, Dexamethasone, Tetramisole, Baralgan, Glybenclamide, Fursemide and other drugs for which prices were upheld;

(c) what is the present price of each of these medicines;

(d) whether it is a fact that courts have directed his Ministry to recover

the overcharged amount from these companies;

(e) if so, whether his Ministry has worked out the amount overcharged on the formulations on Betamethasone; and

(f) if so, what is the amount worked out and how much amount has been collected so far on this account?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) All the concerned companies were advised to implement the prices and the State Drug Controllers were also asked to ensure implementation of prices fixed by Government for these companies.

(b) and (c) The prices of finished medicines in respect of the drugs mentioned in the question are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

(d) Yes, Sir.

(e) and (f) The amount recoverable from the companies would be worked out after hearing is given to the company.

Prices of dexamethasone range drugs

4610. DR. BAPU KALDATE : Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of the companies which have been permitted to produce Dexamethasone, and its salts. Betamethasone and its salts, Dextropropoxyphene, Dipyridamol, Ethambutol, Glybenclamide and Fursemide;

(b) what is the stage from which each is being produced by each company;

(c) whether it is a fact that Government have reduced customs duty on the import of certain raw materials required for the production of these drugs;

(d) if so, what was the price of each drug at the time of reduction of customs duty and what is the present price along with percentage reduction in each case;

(e) whether his Ministry has intervened to reduce the prices proportionatly of any of these drugs;

(f) if so, the names of the drugs and if not, what are the reasons therefor;

(g) whether his Ministry has called for the revised Material Cost data based on present customs duty; and

(h) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Details, to the extent available, are given in the enclosed Statement (*See* below).

(c) Yes, Sir.

(d) The prices of Dexamethasone and its salts, Betamethasone and its salts, Dextropropoxyphene, Dipyridamol, Glybenclamide and Fursemide have not been revised after reduction of customs duty. The price of Ethambutol has been revised